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j ourna l homepage: www.eb iomed ic ine.comEditorialIncreasing Healthspan: Prosper and Live LongIn this editorial of theﬁrst anniversary issue of EBioMedicine, we can-
not help but reﬂect on aging. Tremendous biomedical successes over
the last century have contributed to ever-increasing life expectancies.
In its September 30, 2015World report on ageing and health, the World
Health Organization estimates that the global average life expectancy
is now greater than 60 years. In developed nations, 20% of the popula-
tion is older than 65 years. This proportion is expected to grow to 25%
by 2050, the same time that the global life expectancy reaches greater
than 70 years. An increase in lifespan, though, is not necessarily good
news. Disease risk exponentially increases with age, with older popula-
tions being at greatest risk for cardiovascular disease, cancer, chronic
respiratory illness, musculoskeletal diseases, and neurological and cog-
nitive disorders. Already creaking health care systemsmay be unable to
withstand the impending weight of over one billion elderly patients by
2050. The challenge now is not only how to increase lifespan, but also
how to increase healthspan— the years one spends subjectively content
and without burdensome medical needs.
For time immemorial humans have dreamed of living longer in good
health, questing for the mythical Fountain of Youth. A recent surge in
aging research has brought promise— and hype— to this quest. Basic sci-
ence discoveries in model organisms that experimental manipulations
can delay cellular senescence and increase longevity have positioned
aging as not simply an inevitable, unalterable fact of life but as a modiﬁ-
able biological process. Clinical studies followinghumanpatients longitu-
dinally, while also carefully examining supercentenarians, have provided
other key insights into the genetic and environmental factors affecting
healthy aging. While these ﬁndings have redoubled the efforts of some
for a magical anti-aging pill — a scientiﬁcally and ethically dubious
pursuit— improving people's health in old age has considerable implica-
tions for health care systems facing a looming inﬂux of elderly patients.
So what interventions to increase healthspan are on the horizon?
A mounting body of evidence implicates metabolic systems and
their eventual dysregulation in aging. It is widely recognized that the
simplest ways to improve healthspan are through diet and exercise,
which also tend to increase lifespan by abrogating co-morbidities asso-
ciated with poor health. Among these behavioral interventions, calorie
restriction and even intermittent fasting appear to increase regenerative
capacity and reduce risk for age-related co-morbidities.
While lifestyle modiﬁcations may seem simple to implement for
many, they may not be feasible for some, particularly those already
afﬂicted by other maladies. A growing understanding of the biological
processes underlying aging — the pathways modulating cell growth
and proliferation versus senescence and death — has identiﬁed several
pharmacological targets. Among the ﬁrst were the sirtuin family of pro-
teins, whose activation by the naturally-occurring compound, resvera-
trol, was found to increase healthspan in model organisms. However,
trials in humans have not yielded promising results, and targeting
sirtuins to increase healthspan remains scientiﬁcally controversial.http://dx.doi.org/10.1016/j.ebiom.2015.11.015
2352-3964/© 2015 The Author. Published by Elsevier B.V. This is an open access article underOther pharmacological targets for increasing healthspan are the
mammalian target of rapamycin complexes 1 and 2 (mTORC1 and 2).
Inhibition of mTOR with the US Food and Drug Administration (FDA)-
approved drug, sirolimus, has been shown to increase longevity in a
wide range of organisms, and is now being tested for pro-health effects
in humans. Another mTOR inhibitor, everolimus was recently shown to
improve immune response in elderly patients administered an inﬂuen-
za vaccine, offering hope for mTOR inhibitors in age-dependentmedical
needs. Upstream of mTORC2 is the insulin/insulin-like growth factor 1
(IGF-1) receptor pathway. In model organisms, direct IGF-1 treatment
can extend lifespan, as can inhibition of the downstream modulatory
Ras-Erk complex with the FDA-approved drug, trametinib. Whether
these ﬁndings on mTORC2 translate to improve health in aged human
patients is an area of active investigation — as is the investigation of
mTORC1.
The ﬁrst-line type 2 diabetes drug, metformin, suppresses glucose
production in the liver by activating adenosine-monophosphate-
activated protein kinase (AMPK). AMPK is an endogenous inhibitor of
mTORC1, and the activation of AMPK by metformin has been shown
in model systems and early clinical studies to reduce cell senescence
and increase healthspan. These ﬁndings have led to the recently pro-
posed Targeting Aging with Metformin (TAME) clinical trial where,
for the ﬁrst time, the indication for treatment would be aging itself.
Since aging per se is not currently recognized as a disease, having no
clear clinical endpoint, researchers began discussions with the FDA in
June 2015 to hammer out speciﬁcs of the study. Aging, by far above all
other factors, increases the risk for most diseases, many of which are
co-morbid in the elderly. If metformin treatment is able to improve
healthspan, TAME researchers argue, the age-dependent increased risk
for cancer, cardiovascular disease, and cognitive decline —measurable
clinical endpoints — should be dampened. Opponents argue that rec-
ognizing aging as a disease will cement prejudices against the aged.
Nevertheless, the TAME study has incited policy makers to seriously
consider the ramiﬁcations of aging at both the patient and health care
system levels.
With recent advances in understanding the processes behind aging
and the clinical needs of a growing elderly population, the focus of cur-
rent translational aging research appears to be, wisely, shifting away
from simply increasing lifespan to increasing healthspan. Living longer
can be seen as a beneﬁcial side effect of improving health in old age.
As EBioMedicine ages beyond its ﬁrst year, we also aspire to increase
our healthspan by being the destination journal for publishing ground-
breaking translational research, the side effect of which will be many
more issues for years to come.
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